on Xlife Sciences AG (isin : CH0461929603)
Xlife Sciences AG Focuses on VERAXA's NASDAQ Listing in H1 2025
Xlife Sciences AG reported its 2025 Half-Year performance, highlighting a significant step towards international capital markets with the filing of VERAXA Biotech AG's F-4 prospectus. This move aims at a NASDAQ listing, marking a milestone for both VERAXA and Xlife Sciences.
VERAXA Biotech, which specializes in modern cancer therapies, plans to broaden its investor base through this listing. Additionally, projects like the virus-like particle platform for liver cancer and alliances in Korea show Xlife's commitment to global market integration.
Financially, Xlife recorded revenues of CHF 354,321 for H1 2025. However, earnings per share declined to CHF -0.53. Total assets increased to CHF 536.3 million, although cash reserves decreased to CHF 51.553 million by June's end. Priorities for H2 include supporting VERAXA's NASDAQ endeavor and expanding global partnerships.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Xlife Sciences AG news